Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
JPMorgan Downgrades Novavax (NVAX) to Neutral
May 12, 2021 5:45 AM EDTJPMorgan analyst Eric Joseph downgraded Novavax (NASDAQ: NVAX) from Overweight to Neutral with a price target of $161.00 (from $285.00).
The analyst comments "We are rated Neutral on NVAX shares. While topline UK phase 3 results reported to date have shown compelling efficacy, amid a series of clinical,... More
Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat
May 10, 2021 4:04 PM EDTNovavax (NASDAQ: NVAX) reported Q1 EPS of ($3.05), $0.55 better than the analyst estimate of ($3.60). Revenue for the quarter came in at $447.23 million versus the consensus estimate of $233.9 million.
"Novavax made great strides over the first quarter to pave the path for our COVID-19 vaccine candidate, NVX-CoV2373,... More
